• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom touts continuous glucose monitoring for Type II diabetes patients

August 22, 2017 By Sarah Faulkner

DexcomDexcom (NSDQ:DXCM) touted data today showing that people with Type II diabetes who are using multiple daily injections of insulin can benefit from the use of continuous glucose monitoring.

Those in the 158-patient study using Dexcom’s G4 Platinum CGM system experienced significant A1C reduction and spent more time in target range compared to a control group that used a standard meter to test glucose.

“This study represents a significant step forward for the diabetes community,” lead study investigator Dr. Roy Beck said in prepared remarks. “The results allow us to confidently tell people with Type 2 diabetes using insulin they can use CGM to take control of their disease and make better treatment decisions.”

The study, which was published today in the Annals of Internal Medicine, demonstrated that after 24 weeks, people with Type II diabetes using CGM while on insulin therapy averaged a 0.8% A1C reduction compared to baseline. The group of participants using CGM also increased time in target range by 1.3 hours compared to baseline and 0.6 hours compared to the control group.

Dexcom noted that the participants in the study experienced significant reductions in A1C, regardless of age or education level.

“We have been successful in driving innovation and adoption of CGM in the Type I diabetes community, but this arm of the DIaMonD study is one of the first to examine how well CGM works for people with Type II diabetes on MDI,” president & CEO Kevin Sayer said. “We are pleased to see a significant A1C reduction in this study, showing that the millions of people globally with Type II diabetes on MDI insulin therapy can benefit from CGM use.”

The company also pointed out that at the end of the study, 93% of patients were still using CGM six or more days per week.

DXCM shares were trading at $77.30 in morning activity today, up +5.8%.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals, Wall Street Beat Tagged With: DexCom Inc.

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS